The stock's fall snapped a two-day winning streak.

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

International Assets Investment Management LLC cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 98.4% ...

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Highlights,Bristol-Myers Squibb beats quarterly earnings estimates.,Dividend increased, maintaining strong returns.,Insider ...

The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type ...

Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is ...

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group, congratulates Bristol Myers Squibb, the global biopharmaceutical company, for its recent FDA approval of Cobenfy (KarXT™ ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

Dr. Lubor Gaal joins MitoRx on a part-time basis, bringing over 25 years of global experience in business development, licensing, and strategic partnerships within the pharmaceutical and biotechnology ...

New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.